ClinicalTrials.gg
RecruitingNCT04715646Updated Jul 27, 2026

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

A Phase 3 interventional study of Brivaracetam in Epilepsy, sponsored by UCB Biopharma SRL. Recruiting at 36 sites in 11 countries. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
1 Month and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Planned enrollment
20th of 34
70 · median 94
Started
2021
with 2 others
Phase 3
21 of 34
1 open now
Registered
28th of 34
by date
Lead sponsor
7 of 34
UCB Biopharma SRL

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 20th largest by planned enrollment, is one of 3 that started in 2021, is one of 21 in phase 3, and was the 28th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 1 Month and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.

Read the detailed description

EP0156 is designed to assess the long-term safety and tolerability of BRV in pediatric study participants with epilepsy who participated in the neonatal study N01349 [NCG03325439] and/or have participated in the open-label, long-term, follow-up pediatric study N01266 [NCT01364597]. EP0156 will also assess the long-term safety and tolerability of BRV in Japanese pediatric study participants with partial-onset seizures who will be directly enrolled into the study in Japan. Pharmacokinetic data will also be evaluated in Japanese study participants.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy
  • Brivaracetam
  • Pediatric
  • Child
04

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion criteria for long-term follow-up (LTFU) study participants only

  • Study participants ≥ 1 month of age with a confirmed diagnosis of epilepsy who participated in core study N01266 [NCT01364597] and/or N01349 [NCT03325439]

Inclusion criteria for directly enrolled (DE) study participants in Japan only

  • Study participant is ≥ 4 years to \< 16 years of age
  • Study participant has presence of an electroencephalogram (EEG) reading compatible with the diagnosis of focal epilepsy within the last 10 years
  • Study participant has uncontrolled partial-onset seizure (POS) after an adequate course of treatment with at least 1 antiepileptic drug (AED)
  • Study participant had at least 1 POS during the 4-week Screening Period

Exclusion Criteria:

Exclusion criteria for all study participants

  • Severe medical, neurological, or psychiatric disorders or laboratory values, which may have an impact on the safety of the study participant
  • Study participant is currently participating in another study of an medication (or a medical device) other than brivaracetam (BRV).

Exclusion criteria for long-term follow-up (LTFU) study participants only

- Study participant ≥ 6 years of age has a lifetime history of suicide attempt or has suicidal ideation in the past 6 months as indicated on the Columbia Suicide Severity Rating Scale (C-SSRS)

Exclusion criteria for directly enrolled (DE) study participants in Japan only

  • Study participant has a history of primary generalized epilepsy, psychogenic non-epileptic seizures, or febrile seizures
  • Study participant has a history of status epilepticus in the 30 days prior to the Screening Visit (ScrV) or during the Screening Period
  • Study participant has any illness
  • Study participant has clinically significant laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results
  • Study participant has a clinically significant abnormality
  • Study participant had major surgery within 6 months prior to the ScrV
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Brivaracetam

    LTFU study participants: Up to 5mg/kg/day (for study participants weighing 11kg to less than 20kg) and up to 4mg/kg/day (for study participants weighing 20kg to less than 50kg) and no more than 200mg/day Directly enrolled (DE) study participants: 1mg/kg/day to 4mg/kg/day and no more than 200mg/day.

    Drug: Brivaracetam

Interventions

  • Brivaracetam (BRV) tablets or oral solution will be administered twice daily (bid) in 2 equally divided doses. Tablet strengths: 10 mg, 25 mg, 50 mg Route of administration: oral Oral solution Concentration: 10 mg/ml Route of administration: oral

    Also known as: BRV, Briviact

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs) during the study

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug.

    Time frame: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)

  2. Incidence of treatment-emergent serious adverse events (SAEs) during the study

    A serious adverse event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent disability/incapacity * Is a congenital anomaly or birth defect * Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above

    Time frame: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)

  3. Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of study drug during the study

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug.

    Time frame: From Evaluation Visit (Day 1) until Safety Visits (up to 5 years)

07

Study locations

6 of 36 sites recruiting
  • Ep0156 259
    Hawthorne, New York 10532, United States
    Completed

    Not enrolling at this site — choose another above.

  • Ep0156 237
    Durham, North Carolina 27710, United States
    Completed

    Not enrolling at this site — choose another above.

  • Ep0156 204
    Leuven, Belgium
    Withdrawn

    Not enrolling at this site — choose another above.

  • Ep0156 240
    Prague, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Ep0156 207
    Loos, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Ep0156 209
    Freiburg im Breisgau, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Ep0156 210
    Budapest, Hungary
    Completed

    Not enrolling at this site — choose another above.

  • Ep0156 247
    Budapest, Hungary
    Completed

    Not enrolling at this site — choose another above.

  • Ep0156 232
    Miskolc, Hungary
    Completed

    Not enrolling at this site — choose another above.

  • Ep0156 230
    Roma, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Ep0156 803
    Bunkyō City, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ep0156 808
    Chūō, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ep0156 800
    Gifu, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ep0156 807
    Hiroshima, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ep0156 815
    Kodaira-shi, Japan
    Recruiting
  • Ep0156 813
    Kōshi, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ep0156 806
    Kyoto, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ep0156 811
    Nagoya, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ep0156 812
    Niigata, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ep0156 817
    Osaka, Japan
    Recruiting
  • Ep0156 818
    Ōbu, Japan
    Recruiting
  • Ep0156 819
    Ōmura, Japan
    Recruiting
  • Ep0156 805
    Sapporo, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ep0156 816
    Sendai, Japan
    Recruiting
  • Ep0156 809
    Shimotsuke, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ep0156 814
    Shizuoka, Japan
    Recruiting
  • Ep0156 804
    Tokyo, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ep0156 810
    Yokohama, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ep0156 802
    Yonago, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Ep0156 223
    Aguascalientes, Mexico
    Completed

    Not enrolling at this site — choose another above.

  • Ep0156 609
    Culiacán, Mexico
    Completed

    Not enrolling at this site — choose another above.

  • Ep0156 603
    Guadalajara, Mexico
    Completed

    Not enrolling at this site — choose another above.

  • Ep0156 406
    Kielce, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Ep0156 402
    Krakow, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Ep0156 401
    Poznan, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Ep0156 248
    Seville, Spain
    Completed

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Jul 2030, 111 months after the start.

Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's planned 111 months is above that.

Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2021
First posted
Jan 20, 2021
StartActual
Mar 11, 2021
Primary completionEst.
Jul 8, 2030
CompletionEst.
Jul 8, 2030
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04715646
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jan 20, 2021
Start date
Mar 11, 2021
Primary completion
Jul 8, 2030 (estimated)
Completion
Jul 8, 2030 (estimated)
Last update
Jul 27, 2026

Study contacts

UCB Cares
Contact
UCBCares@ucb.com
0018445992273
UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion